The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Debio 0123-101: A phase 1 trial of Debio 0123 in combination with carboplatin in advanced solid tumors—Safety, pharmacokinetic, and preliminary antitumor activity data.
 
Hans Gelderblom
Research Funding - AmMax Bio (Inst); AmMax Bio (Inst); Daiichi (Inst); Deciphera (Inst); Ipsen (Inst); Novartis (Inst)
 
Mathilde Jalving
Consulting or Advisory Role - AstraZeneca (Inst); GlaxoSmithKline (Inst); Pierre Fabre (Inst)
 
Ingrid Desar
No Relationships to Disclose
 
Omar Saavedra
Travel, Accommodations, Expenses - Affimed Therapeutics
 
Jourik A. Gietema
Research Funding - Abbvie (Inst); Roche/Genentech (Inst); Siemens (Inst)
 
Stefan van Ravensteijn
No Relationships to Disclose
 
Nina Ajmone Marsan
Consulting or Advisory Role - Philips Ultrasound
Speakers' Bureau - Abbott Vascular; GE Healthcare; Philips Ultrasound
Research Funding - Alnylam (Inst); Pfizer (Inst)
 
Anne Bellon
Employment - Debiopharm Group
 
Sandrine Micallef
Employment - Debiopharm Group
Stock and Other Ownership Interests - Roche
 
Noemie Luong
Employment - Debiopharm Group
 
Luke Piggott
Employment - Debiopharm Group
Patents, Royalties, Other Intellectual Property - Debiopharm Group
 
Rikke Frederiksen Franzen
Employment - Debiopharm Group
Stock and Other Ownership Interests - Swedish Orphan Biovitrum
 
Esteban Rodrigo Imedio
Employment - Debiopharm Group
Stock and Other Ownership Interests - BioNTech